Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial.
Bhatt DL, Briggs AH, Reed SD, Annemans L, Szarek M, Bittner VA, Diaz R, Goodman SG, Harrington RA, Higuchi K, Joulain F, Jukema JW, Li QH, Mahaffey KW, Sanchez RJ, Roe MT, Lopes RD, White HD, Zeiher AM, Schwartz GG, Gabriel Steg P; ODYSSEY OUTCOMES Investigators. Bhatt DL, et al. Among authors: gabriel steg p. J Am Coll Cardiol. 2020 May 12;75(18):2297-2308. doi: 10.1016/j.jacc.2020.03.029. J Am Coll Cardiol. 2020. PMID: 32381160 Free article. Clinical Trial.
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.
Schwartz GG, Szarek M, Bittner VA, Diaz R, Goodman SG, Jukema JW, Landmesser U, López-Jaramillo P, Manvelian G, Pordy R, Scemama M, Sinnaeve PR, White HD, Gabriel Steg P; ODYSSEY Outcomes Committees and Investigators. Schwartz GG, et al. Among authors: gabriel steg p. J Am Coll Cardiol. 2021 Aug 3;78(5):421-433. doi: 10.1016/j.jacc.2021.04.102. J Am Coll Cardiol. 2021. PMID: 34325831 Free PMC article. Clinical Trial.
Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial.
Peterson BE, Bhatt DL, Gabriel Steg P, Oldgren J, Maeng M, Zeymer U, Halvorsen S, Hohnloser SH, Lip GYH, Kimura T, Nordaby M, Miede C, Kleine E, Ten Berg JM, Cannon CP; RE-DUAL PCI Steering Committee and Investigators. Peterson BE, et al. Among authors: gabriel steg p. JACC Cardiovasc Interv. 2021 Apr 12;14(7):768-780. doi: 10.1016/j.jcin.2021.02.022. JACC Cardiovasc Interv. 2021. PMID: 33826497 Free article. Clinical Trial.
Early clinical outcomes as a function of use of newer oral P2Y12 inhibitors versus clopidogrel in the EUROMAX trial.
Huber K, Ducrocq G, Hamm CW, van 't Hof A, Lapostolle F, Coste P, Gordini G, Steinmetz J, Verheugt FWA, Adgey J, Nibbe L, Kaniĉ V, Clemmensen P, Zeymer U, Bernstein D, Prats J, Deliargyris EN, Gabriel Steg P. Huber K, et al. Among authors: gabriel steg p. Open Heart. 2017 Nov 28;4(2):e000677. doi: 10.1136/openhrt-2017-000677. eCollection 2017. Open Heart. 2017. PMID: 29225903 Free PMC article.
Association between coffee or tea consumption and cardiovascular outcomes in patients with stable coronary artery disease: Analysis from the CLARIFY registry.
Abtan J, Ducrocq G, Elbez Y, Ferrari R, Ford I, Fox KM, Tardif JC, Tendera M, Danchin N, Parkhomenko A, Reid CM, Gabriel Steg P. Abtan J, et al. Among authors: gabriel steg p. Arch Cardiovasc Dis. 2023 Aug-Sep;116(8-9):382-389. doi: 10.1016/j.acvd.2023.05.007. Epub 2023 Jul 17. Arch Cardiovasc Dis. 2023. PMID: 37524628
Impact of smoking on cardiovascular outcomes in patients with stable coronary artery disease.
Bouabdallaoui N, Messas N, Greenlaw N, Ferrari R, Ford I, Fox KM, Tendera M, P Naidoo D, Hassager C, Gabriel Steg P, Tardif JC; CLARIFY Investigators. Bouabdallaoui N, et al. Among authors: gabriel steg p. Eur J Prev Cardiol. 2021 Oct 25;28(13):1460-1466. doi: 10.1177/2047487320918728. Epub 2020 Apr 27. Eur J Prev Cardiol. 2021. PMID: 34695217
Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial.
Schwartz GG, Gabriel Steg P, Bhatt DL, Bittner VA, Diaz R, Goodman SG, Jukema JW, Kim YU, Li QH, Manvelian G, Pordy R, Sourdille T, White HD, Szarek M; ODYSSEY OUTCOMES Committees and Investigators. Schwartz GG, et al. Among authors: gabriel steg p. Circulation. 2021 Mar 16;143(11):1109-1122. doi: 10.1161/CIRCULATIONAHA.120.049447. Epub 2021 Jan 13. Circulation. 2021. PMID: 33438437 Free PMC article. Clinical Trial.
Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease.
Marston NA, Patel PN, Kamanu FK, Nordio F, Melloni GM, Roselli C, Gurmu Y, Weng LC, Bonaca MP, Giugliano RP, Scirica BM, O'Donoghue ML, Cannon CP, Anderson CD, Bhatt DL, Gabriel Steg P, Cohen M, Storey RF, Sever P, Keech AC, Raz I, Mosenzon O, Antman EM, Braunwald E, Ellinor PT, Lubitz SA, Sabatine MS, Ruff CT. Marston NA, et al. Among authors: gabriel steg p. Circulation. 2021 Feb 2;143(5):470-478. doi: 10.1161/CIRCULATIONAHA.120.051927. Epub 2020 Nov 13. Circulation. 2021. PMID: 33185476 Free PMC article.
Carotid Atherosclerosis Evolution When Targeting a Low-Density Lipoprotein Cholesterol Concentration <70 mg/dL After an Ischemic Stroke of Atherosclerotic Origin.
Amarenco P, Hobeanu C, Labreuche J, Charles H, Giroud M, Meseguer E, Lavallée PC, Gabriel Steg P, Vicaut É, Bruckert E, Touboul PJ. Amarenco P, et al. Among authors: gabriel steg p. Circulation. 2020 Aug 25;142(8):748-757. doi: 10.1161/CIRCULATIONAHA.120.046774. Epub 2020 Jun 29. Circulation. 2020. PMID: 32594766 Clinical Trial.
Benefit of Targeting a LDL (Low-Density Lipoprotein) Cholesterol <70 mg/dL During 5 Years After Ischemic Stroke.
Amarenco P, Kim JS, Labreuche J, Charles H, Giroud M, Lee BC, Mahagne MH, Nighoghossian N, Gabriel Steg P, Vicaut É, Bruckert E; Treat Stroke to Target Investigators. Amarenco P, et al. Among authors: gabriel steg p. Stroke. 2020 Apr;51(4):1231-1239. doi: 10.1161/STROKEAHA.119.028718. Epub 2020 Feb 20. Stroke. 2020. PMID: 32078484 Free article. Clinical Trial.
23 results